{
  "guideline" : {
    "objCls" : "Guideline",
    "@id" : "https://api.pharmgkb.org/data/guideline/PA166128738",
    "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
    "id" : "PA166128738",
    "name" : "Annotation of CPIC Guideline for atazanavir and UGT1A1",
    "history" : [ {
      "id" : 1446898242,
      "date" : "2015-09-18T00:00:00-07:00",
      "type" : "create",
      "version" : 1
    } ],
    "recommendation" : true,
    "relatedChemicals" : [ {
      "objCls" : "Chemical",
      "@id" : "https://api.pharmgkb.org/data/chemical/PA10251",
      "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
      "id" : "PA10251",
      "name" : "atazanavir",
      "version" : 5
    } ],
    "relatedGenes" : [ {
      "objCls" : "Gene",
      "@id" : "https://api.pharmgkb.org/data/gene/PA420",
      "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
      "id" : "PA420",
      "symbol" : "UGT1A1",
      "name" : "UDP glucuronosyltransferase 1 family, polypeptide A1",
      "version" : 6108
    } ],
    "source" : "CPIC",
    "summaryMarkdown" : {
      "id" : 1447982423,
      "externalLinks" : [ ],
      "html" : "<p>The CPIC dosing guideline recommends considering advising individuals who carry two decreased function <em>UGT1A1</em> alleles about a substantial likelihood of developing jaundice, which may cause non-adherence. The dosing guideline recommends that alternative agents be considered if the risk of non-adherence due to jaundice is high. The risk of discontinuation is low and very low for individuals carrying one, or no decreased function <em>UGT1A1</em> alleles, respectively.</p>\n",
      "internalLinks" : [ ],
      "markdown" : "The CPIC dosing guideline recommends considering advising individuals who carry two decreased function _UGT1A1_ alleles about a substantial likelihood of developing jaundice, which may cause non-adherence. The dosing guideline recommends that alternative agents be considered if the risk of non-adherence due to jaundice is high. The risk of discontinuation is low and very low for individuals carrying one, or no decreased function _UGT1A1_ alleles, respectively.",
      "pmids" : [ ],
      "relatedObjects" : [ ],
      "version" : 0
    },
    "terms" : [ {"@id":"https://api.pharmgkb.org/data/ontologyTerm/cpicStatus/cpicStatus:1183847844","@context":"https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":1183847844,"resource":"CPIC Status","term":"A","termId":"cpicStatus:1183847844"} ],
    "textMarkdown" : {
      "id" : 1447982422,
      "externalLinks" : [ "https://cpicpgx.org/", "https://cpicpgx.org/content/guideline/publication/atazanavir/2015/26417955-UGT1A1_allele_frequency.xlsx", "https://cpicpgx.org/content/guideline/publication/atazanavir/2015/26417955-supplement.pdf", "https://cpicpgx.org/content/guideline/publication/atazanavir/2015/26417955.pdf", "https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/" ],
      "html" : "<p>This annotation is based on the <a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fcpicpgx.org%2Fguidelines%2Fguideline-for-atazanavir-and-ugt1a1%2F\" target=\"_blank\">CPIC&reg; guideline for atazanavir and UGT1A1</a>.</p>\n<h3 id=\"april-2016\">April 2016</h3>\n<p><em>Advance online publication September 2015</em></p>\n<ul>\n<li>\n<p>Guidelines regarding the use of pharmacogenomic tests in determining whether atazanavir treatment should be undertaken have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fcpicpgx.org%2F\" target=\"_blank\">(CPIC)</a>.</p>\n</li>\n<li>\n<p>These guidelines are applicable to:</p>\n<ul>\n<li>Adults</li>\n<li>At the time of this writing there are no pediatric data regarding associations between <em>UGT1A1</em> genotypes and likelihood of bilirubin-related discontinuation of atazanavir. However, <em>UGT1A1</em> genotypes are expected to affect atazanavir-related hyperbilirubinemia similarly in adults and children. Therefore, recommendations for adults may be directly adapted to pediatric patients.</li>\n</ul>\n</li>\n<li>\n<p>Download and read:</p>\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fcpicpgx.org%2Fcontent%2Fguideline%2Fpublication%2Fatazanavir%2F2015%2F26417955.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium Guidelines for Atazanavir and <em>UGT1A1</em> Prescribing</a>.</li>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fcpicpgx.org%2Fcontent%2Fguideline%2Fpublication%2Fatazanavir%2F2015%2F26417955-supplement.pdf\" target=\"_blank\">2015 Supplement</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fcpicpgx.org%2Fcontent%2Fguideline%2Fpublication%2Fatazanavir%2F2015%2F26417955-UGT1A1_allele_frequency.xlsx\" target=\"_blank\">UGT1A1 Allele Frequencies</a></li>\n</ul>\n</li>\n</ul>\n<h3 id=\"table-1-recommended-therapeutic-use-of-atazanavir-based-on-ugt1a1-genotype\">Table 1: Recommended therapeutic use of atazanavir based on <em>UGT1A1</em> genotype</h3>\n<p><em>Adapted from Tables 1 and 2 of the 2015 guideline manuscript.</em></p>\n<table class=\"table\">\n<thead>\n<tr><th>Likely phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications for phenotypic measures</th><th>Recommendations for atazanavir therapy</th><th>Classification of recommendation for atazanavir therapy</th></tr>\n</thead>\n<tbody>\n<tr><td>Extensive Metabolizer</td><td>An individual carrying 2 reference <sup>b</sup> function and/or increased function alleles; or individuals of genotype CC at <a href=\"/variant/PA166155607\">rs887829</a></td><td>*1/*1; *1/*36; *36/*36; <a href=\"/variant/PA166155607\">rs887829</a> CC</td><td>Reference <sup>c</sup> UGT1A1 activity; very low likelihood of bilirubin-related discontinuation of atazanavir.</td><td>There is no need to avoid prescribing of atazanavir based on <em>UGT1A1</em> genetic test result.</td><td>Strong</td></tr>\n<tr><td>Intermediate Metabolizer</td><td>An individual carrying one reference <sup>b</sup> function (*1) <sup>c</sup> or increased function allele (*36) plus one decreased function allele (*6, *28, *37). Alternatively identified by heterozygosity for <a href=\"/variant/PA166155607\">rs887829</a> C/T.</td><td>*1/*28; *1/*37; *36/*28; *36/*37; <a href=\"/variant/PA166155607\">rs887829</a> C/T, *1/*6</td><td>Somewhat decreased UGT1A1 activity; low likelihood of bilirubin-related discontinuation of atazanavir.</td><td>There is no need to avoid prescribing of atazanavir based on <em>UGT1A1</em> genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient’s genotype makes this unlikely</td><td>Strong</td></tr>\n<tr><td>Poor Metabolizer</td><td>An individual carrying two decreased function alleles (*6, *28, *37). Alternatively identified by homozygosity for <a href=\"/variant/PA166155607\">rs887829</a> T/T (*80/*80)</td><td>*28/*28; *28/*37; *37/*37; <a href=\"/variant/PA166155607\">rs887829</a> T/T (*80/*80), *6/*6 <sup>a</sup></td><td>Markedly decreased UGT1A1 activity; high likelihood of bilirubin-related discontinuation of atazanavir.</td><td>Consider an alternative agent particularly where jaundice would be of concern to the patient.</td><td>Strong</td></tr>\n</tbody>\n</table>\n<p><sup>a</sup> Homozygosity for UGT1A1*6, which occurs almost exclusively in individuals of Asian descent, is associated with Gilbert syndrome. However, at this time, it is unclear if patients with this diplotype are at increased risk of severe atazanavir-associated hyperbilirubinemia.</p>\n<p><sup>b</sup> “reference” function refers to the UGT1A1 alleles to which other alleles are compared.</p>\n<p><sup>c</sup> The reference function *1 allele is a fully functional refers to the <a href=\"/variant/PA166159020\">rs8175347</a> TA6 allele.</p>\n",
      "internalLinks" : [ ],
      "markdown" : "This annotation is based on the [CPIC&reg; guideline for atazanavir and UGT1A1](https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/).\n\n## April 2016\n\n_Advance online publication September 2015_\n- Guidelines regarding the use of pharmacogenomic tests in determining whether atazanavir treatment should be undertaken have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium [(CPIC)](https://cpicpgx.org/ ).\n\n- These guidelines are applicable to:\n  - Adults\n  - At the time of this writing there are no pediatric data regarding associations between _UGT1A1_ genotypes and likelihood of bilirubin-related discontinuation of atazanavir. However, _UGT1A1_ genotypes are expected to affect atazanavir-related hyperbilirubinemia similarly in adults and children. Therefore, recommendations for adults may be directly adapted to pediatric patients.\n- Download and read:\n  - [Clinical Pharmacogenetics Implementation Consortium Guidelines for Atazanavir and _UGT1A1_ Prescribing](https://cpicpgx.org/content/guideline/publication/atazanavir/2015/26417955.pdf).\n  - [2015 Supplement](https://cpicpgx.org/content/guideline/publication/atazanavir/2015/26417955-supplement.pdf)\n  - [UGT1A1 Allele Frequencies](https://cpicpgx.org/content/guideline/publication/atazanavir/2015/26417955-UGT1A1_allele_frequency.xlsx)\n\n## Table 1: Recommended therapeutic use of atazanavir based on _UGT1A1_ genotype\n\n_Adapted from Tables 1 and 2 of the 2015 guideline manuscript._\n\n| Likely phenotype | Genotypes | Examples of diplotypes | Implications for phenotypic measures   | Recommendations for atazanavir therapy | Classification of recommendation for atazanavir therapy |\n| --- | --- | --- | --- | --- | --- |\n|Extensive Metabolizer | An individual carrying 2 reference ^b^ function and/or increased function alleles; or individuals of genotype CC at [variant:rs887829] | *1/*1; *1/*36; *36/*36; [variant:rs887829] CC| Reference ^c^ UGT1A1 activity; very low likelihood of bilirubin-related discontinuation of atazanavir.  |  There is no need to avoid prescribing of atazanavir based on _UGT1A1_ genetic test result.  |  Strong |\n|Intermediate Metabolizer  | An individual carrying one reference ^b^ function (*1) ^c^ or increased function allele (*36) plus one decreased function allele (*6, *28, *37). Alternatively identified by heterozygosity for [variant:rs887829] C/T. | *1/*28; *1/*37; *36/*28; *36/*37; [variant:rs887829] C/T, *1/*6 | Somewhat decreased UGT1A1 activity; low likelihood of bilirubin-related discontinuation of atazanavir. | There is no need to avoid prescribing of atazanavir based on _UGT1A1_ genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient’s genotype makes this unlikely |  Strong |\n|Poor Metabolizer  | An individual carrying two decreased function alleles (*6, *28, *37). Alternatively identified by homozygosity for [variant:rs887829] T/T (*80/*80) | *28/*28; *28/*37; *37/*37; [variant:rs887829] T/T (*80/*80), *6/*6 ^a^ | Markedly decreased UGT1A1 activity; high likelihood of bilirubin-related discontinuation of atazanavir. | Consider an alternative agent particularly where jaundice would be of concern to the patient. |  Strong |\n\n^a^ Homozygosity for UGT1A1*6, which occurs almost exclusively in individuals of Asian descent, is associated with Gilbert syndrome. However, at this time, it is unclear if patients with this diplotype are at increased risk of severe atazanavir-associated hyperbilirubinemia.\n\n^b^ “reference” function refers to the UGT1A1 alleles to which other alleles are compared.\n\n^c^ The reference function *1 allele is a fully functional refers to the [variant:rs8175347] TA6 allele.",
      "pmids" : [ ],
      "relatedObjects" : [ "PA166155607", "PA166159020" ],
      "version" : 9
    },
    "version" : 32,
    "xrefs" : [ {"@id":"https://api.pharmgkb.org/data/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/","@context":"https://www.pharmgkb.org/jsonld/crossReference.jsonld","id":1447983449,"name":"Based on a CPIC dosing guideline","resource":"Web Resource","sameAs":"https%3A%2F%2Fcpicpgx.org%2Fguidelines%2Fguideline-for-atazanavir-and-ugt1a1%2F","xrefId":"https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/"} ]
  },
  "annotationGroups" : [ {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166162570",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166162570",
    "name" : "Indeterminate",
    "annotations" : [ {
      "id" : 1448569223,
      "history" : [ {
        "id" : 1448569221,
        "date" : "2017-01-30T21:15:15.449-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1448569222,
        "externalLinks" : [ ],
        "html" : "<p>N/A</p>\n",
        "internalLinks" : [ ],
        "markdown" : "N/A",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1448569226,
      "history" : [ {
        "id" : 1448569224,
        "date" : "2017-01-30T21:15:38.941-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1448569225,
        "externalLinks" : [ ],
        "html" : "<p>Indeterminate</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Indeterminate",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "description" : "Likely phenotype of metabolizer status",
        "resource" : "Guideline Tags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1448569220,
      "history" : [ {
        "id" : 1448569218,
        "date" : "2017-01-30T21:15:06.706-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1448569219,
        "externalLinks" : [ ],
        "html" : "<p>An individual carrying one or two unknown function alleles.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "An individual carrying one or two unknown function alleles.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1448569229,
      "history" : [ {
        "id" : 1448569227,
        "date" : "2017-01-30T21:15:56.512-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1448569228,
        "externalLinks" : [ ],
        "html" : "<p>This guideline does not contain recommendations for this allele combination.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "This guideline does not contain recommendations for this allele combination.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 0
    } ],
    "genePhenotypes" : [ ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166128738",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166128738",
      "name" : "Annotation of CPIC Guideline for atazanavir and UGT1A1",
      "version" : 32
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602495",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602495,
      "resource" : "Prescribing Change",
      "term" : "No",
      "termId" : "rxChange:1448602495",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501929,
      "description" : "Not Applicable",
      "resource" : "Guideline Strength",
      "term" : "N/A",
      "termId" : "guidelineStrength:981501929",
      "version" : 1
    },
    "version" : 1
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128739",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128739",
    "name" : "Normal Metabolizer",
    "annotations" : [ {
      "id" : 1445558348,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986766,
        "externalLinks" : [ ],
        "html" : "<p>Reference UGT1A1 activity; very low likelihood of bilirubin-related discontinuation of atazanavir.</p>\n<p><em>“Reference” function refers to the UGT1A1 allele to which other alleles are compared.</em></p>\n",
        "internalLinks" : [ ],
        "markdown" : "Reference UGT1A1 activity; very low likelihood of bilirubin-related discontinuation of atazanavir.\n\n_“Reference” function refers to the UGT1A1 allele to which other alleles are compared._",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 7
    }, {
      "id" : 1448569200,
      "history" : [ {
        "id" : 1448569198,
        "date" : "2017-01-30T20:50:14.187-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1448569199,
        "externalLinks" : [ ],
        "html" : "<p>Normal Metabolizer</p>\n<p><em>CPIC Term Standardization Project recommended replacing the term ‘extensive’ metabolizer with ‘normal’ metabolizer [Article:<a href=\"/pmid/27441996\">27441996</a>] for drug metabolizing enzymes.</em></p>\n",
        "internalLinks" : [ ],
        "markdown" : "Normal Metabolizer\n\n_CPIC Term Standardization Project recommended replacing the term ‘extensive’ metabolizer with ‘normal’ metabolizer [PMID:27441996] for drug metabolizing enzymes._",
        "pmids" : [ "27441996" ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "description" : "Likely phenotype of metabolizer status",
        "resource" : "Guideline Tags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1445558347,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986765,
        "externalLinks" : [ ],
        "html" : "<p>An individual carrying 2 reference function and/or increased function alleles; or individuals of genotype CC at <a href=\"/variant/PA166155607\">rs887829</a></p>\n<p><em>The term 'reference' function refers to the UGT1A1 alleles to which other alleles are compared. The reference function *1 allele is fully functional and refers to the rs8175347 TA6 allele.</em></p>\n",
        "internalLinks" : [ ],
        "markdown" : "An individual carrying 2 reference function and/or increased function alleles; or individuals of genotype CC at [variant:rs887829]\n\n_The term 'reference' function refers to the UGT1A1 alleles to which other alleles are compared. The reference function *1 allele is fully functional and refers to the rs8175347 TA6 allele._",
        "pmids" : [ ],
        "relatedObjects" : [ "PA166155607" ],
        "version" : 5
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 10
    }, {
      "id" : 1445558349,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986767,
        "externalLinks" : [ ],
        "html" : "<p>There is no need to avoid prescribing of atazanavir based on <em>UGT1A1</em> genetic test result.</p>\n<p><em>Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient’s genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).</em></p>\n",
        "internalLinks" : [ ],
        "markdown" : "There is no need to avoid prescribing of atazanavir based on _UGT1A1_ genetic test result.\n\n_Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient’s genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice)._",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 7
    } ],
    "genePhenotypes" : [ "UGT1A1:Increased Function/Increased Function", "UGT1A1:Increased Function/Normal Function", "UGT1A1:Normal Function/Normal Function" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166128738",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166128738",
      "name" : "Annotation of CPIC Guideline for atazanavir and UGT1A1",
      "version" : 32
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602495",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602495,
      "resource" : "Prescribing Change",
      "term" : "No",
      "termId" : "rxChange:1448602495",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "resource" : "Guideline Strength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930",
      "version" : 0
    },
    "version" : 12
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128740",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128740",
    "name" : "Intermediate Metabolizer",
    "annotations" : [ {
      "id" : 1445558351,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986769,
        "externalLinks" : [ ],
        "html" : "<p>Somewhat decreased UGT1A1 activity; low likelihood of bilirubin- related discontinuation of atazanavir.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Somewhat decreased UGT1A1 activity; low likelihood of bilirubin- related discontinuation of atazanavir.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1448569196,
      "history" : [ {
        "id" : 1448569194,
        "date" : "2017-01-30T20:48:30.640-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1448569195,
        "externalLinks" : [ ],
        "html" : "<p>Intermediate Metabolizer</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Intermediate Metabolizer",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "description" : "Likely phenotype of metabolizer status",
        "resource" : "Guideline Tags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1445558352,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986770,
        "externalLinks" : [ ],
        "html" : "<p>An individual carrying one reference function (*1) or increased function allele (*36) plus one decreased function allele (*6, *28, *37). Alternatively identified by heterozygosity for <a href=\"/variant/PA166155607\">rs887829</a> C/T.</p>\n<p><em>The term 'reference' function refers to the UGT1A1 alleles to which other alleles are compared. The reference function *1 allele is fully functional and refers to the rs8175347 TA6 allele.</em></p>\n",
        "internalLinks" : [ ],
        "markdown" : "An individual carrying one reference function (*1) or increased function allele (*36) plus one decreased function allele (*6, *28, *37). Alternatively identified by heterozygosity for [variant:rs887829] C/T.\n\n_The term 'reference' function refers to the UGT1A1 alleles to which other alleles are compared. The reference function *1 allele is fully functional and refers to the rs8175347 TA6 allele._",
        "pmids" : [ ],
        "relatedObjects" : [ "PA166155607" ],
        "version" : 5
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 10
    }, {
      "id" : 1445558353,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986768,
        "externalLinks" : [ ],
        "html" : "<p>There is no need to avoid prescribing of atazanavir based on <em>UGT1A1</em> genetic test result.</p>\n<p><em>Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient’s genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).</em></p>\n",
        "internalLinks" : [ ],
        "markdown" : "There is no need to avoid prescribing of atazanavir based on _UGT1A1_ genetic test result. \n\n_Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient’s genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice)._",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 7
    } ],
    "genePhenotypes" : [ "UGT1A1:Decreased Function/Increased Function", "UGT1A1:Decreased Function/Normal Function" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166128738",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166128738",
      "name" : "Annotation of CPIC Guideline for atazanavir and UGT1A1",
      "version" : 32
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602495",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602495,
      "resource" : "Prescribing Change",
      "term" : "No",
      "termId" : "rxChange:1448602495",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "resource" : "Guideline Strength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930",
      "version" : 0
    },
    "version" : 12
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128741",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128741",
    "name" : "Poor Metabolizer",
    "annotations" : [ {
      "id" : 1445558354,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986771,
        "externalLinks" : [ ],
        "html" : "<p>Markedly decreased UGT1A1 activity; high likelihood of bilirubin- related discontinuation of atazanavir.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Markedly decreased UGT1A1 activity; high likelihood of bilirubin- related discontinuation of atazanavir.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1448569213,
      "history" : [ {
        "id" : 1448569211,
        "date" : "2017-01-30T21:08:18.338-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1448569212,
        "externalLinks" : [ ],
        "html" : "<p>Poor Metabolizer</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Poor Metabolizer",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "description" : "Likely phenotype of metabolizer status",
        "resource" : "Guideline Tags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1445558355,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986772,
        "externalLinks" : [ ],
        "html" : "<p>An individual carrying two decreased function alleles (*6, *28, *37). Alternatively identified by homozygosity for <a href=\"/variant/PA166155607\">rs887829</a> T/T (*80/*80).</p>\n<p><em>Homozygosity for UGT1A1 *6, which occurs almost exclusively in individuals of Asian descent, is associated with Gilbert syndrome. However, at this time, it is unclear if patients with this diplotype are at increased risk of severe atazanavir-associated hyperbilirubinemia.</em></p>\n",
        "internalLinks" : [ ],
        "markdown" : "An individual carrying two decreased function alleles (*6, *28, *37). Alternatively identified by homozygosity for [variant:rs887829] T/T (*80/*80).\n\n_Homozygosity for UGT1A1 *6, which occurs almost exclusively in individuals of Asian descent, is associated with Gilbert syndrome. However, at this time, it is unclear if patients with this diplotype are at increased risk of severe atazanavir-associated hyperbilirubinemia._",
        "pmids" : [ ],
        "relatedObjects" : [ "PA166155607" ],
        "version" : 5
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 10
    }, {
      "id" : 1445558356,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986773,
        "externalLinks" : [ ],
        "html" : "<p>Consider an alternative agent particularly where jaundice would be of concern to the patient.</p>\n<p><em>If atazanavir is to be prescribed, there is a high likelihood of developing jaundice that will result in atazanavir discontinuation (at least 20% and as high as 60%).</em></p>\n",
        "internalLinks" : [ ],
        "markdown" : "Consider an alternative agent particularly where jaundice would be of concern to the patient. \n\n_If atazanavir is to be prescribed, there is a high likelihood of developing jaundice that will result in atazanavir discontinuation (at least 20% and as high as 60%)._",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 7
    } ],
    "genePhenotypes" : [ "UGT1A1:Decreased Function/Decreased Function" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166128738",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166128738",
      "name" : "Annotation of CPIC Guideline for atazanavir and UGT1A1",
      "version" : 32
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602497",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602497,
      "resource" : "Prescribing Change",
      "term" : "Yes",
      "termId" : "rxChange:1448602497",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "resource" : "Guideline Strength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930",
      "version" : 0
    },
    "version" : 12
  } ],
  "genePhenotypes" : {
    "UGT1A1" : {
      "*1" : "Normal Function",
      "*6" : "Decreased Function",
      "*27" : "Decreased Function",
      "*28" : "Decreased Function",
      "*36" : "Increased Function",
      "*37" : "Decreased Function",
      "*60" : "Normal Function",
      "*80" : "Decreased Function"
    }
  },
  "citations" : [ {
    "@id" : "https://api.pharmgkb.org/data/literature/26417955",
    "@context" : "https://api.pharmgkb.org/data/literature.jsonld",
    "id" : 15093021,
    "resourceId" : "26417955",
    "title" : "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing",
    "authors" : [ "Gammal Roseann S", "Court Michael H", "Haidar Cyrine E", "Iwuchukwu Otito Frances", "Gaur Aditya H", "Alvarellos Maria", "Guillemette Chantal", "Lennox Jeffrey L", "Whirl-Carrillo Michelle", "Brummel Sean", "Ratain Mark J", "Klein Teri E", "Schackman Bruce R", "Caudle Kelly E", "Haas David W" ],
    "hasKeyword" : true,
    "journal" : "Clinical pharmacology and therapeutics",
    "meshDiseases" : [ ],
    "meshTerms" : [ ],
    "month" : 9,
    "nonHuman" : false,
    "pubDate" : "2015-09-01T00:00:00-07:00",
    "sameAs" : "https://www.ncbi.nlm.nih.gov/pubmed/26417955",
    "sentences" : [ {
      "text" : "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing",
      "location" : "title",
      "id" : 15093022,
      "sentenceIndex" : 0
    }, {
      "text" : "The antiretroviral protease inhibitor atazanavir inhibits hepatic uridine diphosphate glucuronosyltransferase (UGT) 1A1, thereby preventing the glucuronidation and elimination of bilirubin.",
      "location" : "abstract",
      "id" : 15093023,
      "sentenceIndex" : 1
    }, {
      "text" : "Resultant indirect hyperbilirubinemia with jaundice can cause premature discontinuation of atazanavir.",
      "location" : "abstract",
      "id" : 15093024,
      "sentenceIndex" : 2
    }, {
      "text" : "Risk for bilirubin-related discontinuation is highest among individuals who carry two UGT1A1 decreased function alleles (UGT1A1*28 or *37).",
      "location" : "abstract",
      "id" : 15093025,
      "sentenceIndex" : 3
    }, {
      "text" : "We summarize published literature that supports this association and provide recommendations for atazanavir prescribing when UGT1A1 genotype is known (updates at www.pharmgkb.org).",
      "location" : "abstract",
      "id" : 15093026,
      "sentenceIndex" : 4
    }, {
      "text" : "This article is protected by copyright.",
      "location" : "abstract",
      "id" : 15093027,
      "sentenceIndex" : 5
    }, {
      "text" : "All rights reserved.",
      "location" : "abstract",
      "id" : 15093028,
      "sentenceIndex" : 6
    } ],
    "summary" : "The antiretroviral protease inhibitor atazanavir inhibits hepatic uridine diphosphate glucuronosyltransferase (UGT) 1A1, thereby preventing the glucuronidation and elimination of bilirubin. Resultant indirect hyperbilirubinemia with jaundice can cause premature discontinuation of atazanavir. Risk for bilirubin-related discontinuation is highest among individuals who carry two UGT1A1 decreased function alleles (UGT1A1*28 or *37). We summarize published literature that supports this association and provide recommendations for atazanavir prescribing when UGT1A1 genotype is known (updates at www.pharmgkb.org). This article is protected by copyright. All rights reserved.",
    "type" : "article",
    "version" : 1,
    "year" : 2015
  } ]
}